Cocrystal Pharma, Inc. Cash Flow Statement
COCP|4 years of annual SEC 10-K data (FY2012-FY2021)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
Cocrystal Pharma, Inc. used $13M in operating cash flow and negative free cash flow of $13M in FY2021.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 14.87 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2021 | FY2020 | FY2019 | FY2012 |
|---|---|---|---|---|
| Net Income | -$14.2M | -$48.2M | -$49.0M | -$8.0M |
| Depreciation & Amortization | $190.0K | $98.0K | $50.0K | $138.6K |
| Operating Cash Flow | -$12.7M | -$1.6M | -$8.3M | -$1.6M |
| Capital Expenditures | $52.0K | $145.0K | $28.0K | $152.1K |
| Free Cash Flow | -$12.8M | -$1.7M | -$8.3M | -$1.7M |
| FCF Margin | - | -26.0% | -126.7% | - |